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The prevalence of semen hyperviscosity (SHV) is
estimated to be between 12-29% and can lead to male
factor infertility both in vivo and in vitro. Semen is
composed of fluids secreted by the male accessory glands,
which contain proteins essential to the coagulation and
liquefaction of semen. Hypofunction of the prostate or
seminal vesicles causes abnormal viscosity of seminal
fluid. Infection and high levels of seminal leukocytes may
also result in the development of SHV. Oxidative stress and
biochemical and genetic factors can furthermore contribute
to this condition. Hyperviscosity can impair normal sperm
movement in the female reproductive tract, and can lead to
decreased sperm count. SHV is treated with a hypodermic
needle, mucolytic enzymes, antibiotics and anti-
inflammatory agents in certain cases. Further research is
needed to better understand the contributors to SHV and
the treatments that can be used for infertile males with
hyperviscous semen.
. INTRODUCTION
Male factor infertility contributes to the
fertility problems of roughly 30-40% of subfertile
couples, and is the sole contributor in 20% of infertile
couples (1).  Known causes of male factor infertility
include oxidative stress (OS) and reactive oxygen
species (ROS), as well as clinical diseases such as
leukocytospermia, varicocele, and unexplained
infertility, which can lead to a decrease in semen
parameters and DNA damage of spermatozoa. These
diseases potentially result in abnormal semen
characteristics, which affect semen parameters. Other
contributing factors include infection, inflammation, and
dysfunction of the male sex glands, which gives rise to
decreased sperm motility and increased levels of
leukocytes. Semen hyperviscosity (SHV) is another
condition that can contribute to male subfertility as it is
associated with changes in the chemical and physical
characteristics of semen (2).
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Directly after ejaculation semen coagulates
before gradual liquefaction occurs. Semen usually loses its
viscosity during the liquefaction process, both in vitro and
in vivo (in the female reproductive tract) (3). However, in
the event that semen retains some of the viscous
characteristics, it can be identified and is regarded as
hyperviscous (2). Seminal hyperviscosity occurs in 12%–
29% of ejaculates (4, 5) and may be a cause of male
infertility. Hyperviscous seminal fluid has been shown to
have a negative impact of sperm motility and semen quality
(2, 6), and contributes to a poor outcome with in vitro
fertilization (7). SHV is likely caused by infection,
inflammation, dysfunction of the male sex glands, and
diseases that directly impact male fertility. While these
conditions are related to SHV, the exact mechanisms
through which the coagulated characteristics are retained
are still not clear (8). Hyperviscous seminal fluid results in
a negative impact on fertility through its role in the female
genital tract. The various causes of hyperviscosity
contribute to male subfertility outside the scope of SHV.
Assessment and treatment of hyperviscous semen has
improved in recent years, but the mechanisms through
which hyperviscosity affect fertility are still being debated.
The purpose of this review is to evaluate and
appraise current research and literature concerning SHV.
The focus is on the causes of SHV and the conditions
associated with the diagnosis, the role and consequences of
SHV in male fertility, as well as the treatments available
both in vivo and in vitro to improve fertility for those with
hyperviscous semen.
3. SEMEN AND ITS CONSTITUENTS
Semen consists of spermatozoa suspended in a
fluid medium referred to as seminal plasma. The seminal
plasma component of semen provides nutrients and
protection to spermatozoa in the female reproductive tract
as it protects spermtozoa from the acidic environment and
possible DNA damage. Seminal plasma is composed of
fluids secreted by the testes, epididymis, seminal vesicles,
prostate, and bulbourethral glands (9). The fluid secreted by
the seminal vesicles makes up the majority of the seminal
plasma and is high in fructose (10), which provides the
necessary energy for normal sperm function. Secretions
from the prostate contain lipids, citric acid, proteolytic
enzymes, zinc, and acid phosphatase, while the fluid
secreted by the bulbourethral glands functions as a
lubricant for the urethra. The testes contribute to the
composition of semen by producing millions of
spermatozoa, while the Sertoli cells secrete a quantity of
fluid to act as a suspension medium and assist in the
transport of sperm from the seminiferous tubules, after
spermiation, through the different genital ducts.
Subsequently to ejaculation, semen coagulates as
a result of vesicular and epididymal proteins present in the
seminal plasma (11, 12). Sperm gain motility, after being
freed from the seminal clot by the action of proteolytic
enzymes secreted by the seminal vesicles following
liquefaction of the coagulum, approximately 20-30 minutes
after ejaculation (13).
4. DEFINING AND ASESSING SHV
Once liquefied, seminal fluid exhibits varying
degrees of tensile strength and thickness, commonly
referred to as viscosity. Normally, liquefied semen has low
viscosity. Semen that retains some of its viscous properties
post-ejaculation, which does not change over time, can be
regarded as hyperviscous. SHV has varying grades of
disease. According to the World Health Organization
(WHO), diagnosis is based on the thread length formed by
liquefied semen (14). The viscosity of the semen sample
can be estimated by gently aspirating it into a wide-bore
plastic disposable pipette (±1.5 mm diameter) and
subsequently allowing it to drop by gravity. A normal
sample leaves the pipette in small discrete drops, but if
viscosity is abnormal (increased), the drop will form a
thread more than 2 cm long. Alternatively, the viscosity can
be evaluated by placing a glass rod into the sample and
observing the length of the thread that forms upon
withdrawal of the rod. The viscosity should also be
recorded as abnormal when the thread exceeds 2 cm in
length (14). These evaluations measure the visco-elasticity
of the semen.
In contrast to a partially liquefied sample, a
viscous semen specimen exhibits homogeneous stickiness
and its consistency will not change with time. SHV can be
recognized by the elastic properties of the sample, which
adheres strongly to itself when attempts are made to pipette
it (14).
The thread lengths of the semen drops can be
measured on a centimeter scale in order to determine the
grade of viscosity. Men whose semen has a thread length
between 2cm and 4cm are diagnosed with mild SHV; a
thread length between 4cm and 6cm is labeled as moderate
SHV; and a thread length greater than 6cm is diagnosed as
severe SHV (15). In a study performed by Elia and co-
workers it was shown that the prevalence of SHV was as
high as 26.6% in males from infertile couples (15). It was
found that 13.1% of the men had mild SHV, while 6.6% of
men had moderate SHV, with 6.4% of men diagnosed with
severe SHV (15).
A more quantitative method of assessing
viscosity levels in semen samples is through the use of
capillary-loaded semen analysis chambers. Despite this
being a time consuming and expensive exercise, results are
believed to be more objective and reliable (16). Semen
viscosity is measured by the filling time of the capillary;
theoretically, there should be a relationship between the
degree of viscosity and the time taken to fill a capillary of a
certain diameter and at a certain angle (17). A study by
Rijnders et al. found that this method of measuring semen
viscosity was accurate 89.1% of the time (16). They
concluded that both diameter of the capillary and angle of
contact between semen and capillary were important in
assessment, as well as whether or not seminal plasma was
filtered. This method can be used in conjunction with
viscosity meters; however, the use of a viscosity meter




Figure 1. The various causes and consequences of semen
hyperviscosity. Several contributors may ultimately lead to
infertility or subfertility.
Normal semen rarely prevents sperm movement;
however, hyperviscous semen produces impaired sperm
motility and asthenozoospermia. SHV may create a
trapping effect due to the visco-elasticity of the seminal
plasma that inhibits normal sperm motility (6, 18). In
addition, the tensile properties of semen have been shown
to have an impact on the amount of energy spermatozoa
need to expend in order to achieve a certain velocity.
Emami et al. recently found kallikrein-related peptidases
(KLKs), a type of human protease, to be differentially
expressed when compared between semen samples grouped
by sperm quality, including motility, speed, concentration,
volume, and pH. They found that the expression level of
seminal plasma KLKs correlates with liquefaction and
viscosity, and may be used in diagnosis of SHV (19).
SHV can also potentially be used as a biomarker
for the level of secretory activity of the seminal vesicles
and prostate (5). Hyperviscosity of semen has been
correlated with decreased fructose and phosphorous levels.
A similar correlation was observed in semen that took
longer than two hours to liquefy. Zinc concentrations have
been found to be lower in hyperviscous samples.
Hyperviscosity has been shown to correlate with prostate
and seminal vesicle dysfunction, although hyperviscosity is
commonly found in men with functionally normal
accessory sex glands (5).
5. CONTRIBUTORS TO SHV
There are many known causes of SHV as well as
several hypothesized contributors and associated factors
(see Figure 1), although the exact cause of abnormal semen
viscosity after coagulation and liquefaction is unclear (8).
SHV is most attributed to male accessory gland infection,
increased levels of leukocytes, and inflammation, as well as
dysfunction of the sex glands or even the immune system
(20). While these hypotheses are generally accepted by
clinicians, conflicting scientific evidence have been
reported in the literature. Munuce et al. found no
association between hyperviscosity of semen samples and
the number of positive bacterial cultures or the number of
species in each sample, including Mycoplasma hominis,
Ureaplasma urealyticum, and Chlamydia trachomatis (21).
In addition, they reported no association between the
presence of leukocytospermia or sperm antibodies and
SHV. They concluded that SHV does not necessarily reveal
a genito-urinary tract infection (21). In another study,
researchers again did not find an association between
antisperm antibodies and leukocytospermia (22), although
leukocytospermia is sometimes associated with conditions
other than infection, such as varicocele (23). Leukocytes
still play an important role in the development of SHV, as
they are present in cases of infection, are major sources of
ROS, and are involved in the transmission of retroviruses
(24).
It has been reported that bacteria culture-positive
semen samples were more likely to be hyperviscous than
non-positive samples (25). This is explained by
inflammation and the presence of leukocytes or antibodies,
or possibly the metabolic by-products of bacterial growth
(26, 27). The WHO determined that increased semen
viscosity or impairment of liquefaction is often established
in patients with a genito-urinary tract infection and other
abnormal sperm characteristics as opposed to in men with
infection and normal sperm characteristics (28). In a study
by Moulik et al. it was determined that a correlation existed
between the presence of sperm antibodies and hyperviscous
semen (29).
Elevated amounts of seminal leukocytes
contribute to OS. When excess levels of ROS and reactive
nitrogen species (RNS) are imbalanced in respect to levels
of antioxidants, which are agents that are able to scavenge
free radicals, OS can occur. ROS and oxidative damage
may play a role in SHV; OS is associated with conditions
that affect male fertility such as leukocytospermia,
varicocele, idiopathic infertility, and genito-urinary tract
infection, along with other factors including smoking and
exposure to environmental pollution. It has already been
reported that higher levels of ROS are found in the seminal
plasma and sperm of infertile men (30). Similarly OS and
OS-related conditions have been associated with
hyperviscous blood (31). Malondialdehyde (MDA) and
carbonyl detection are indicative of ROS levels and
oxidative damage. High levels of MDA and carbonyl in
blood have been associated with higher blood viscosity
(31). Correlations have been found between hyperviscous
semen and levels of MDA and carbonyl in males with
subfertility (32). This suggests that OS may be a
contributor to SHV. Increasing levels of MDA and protein
carbonyls were shown to correlate with increasing degrees
of viscosity of semen in infertile men (32). Low levels of
antioxidants have been correlated with SHV (33);
decreased antioxidant capacities in seminal fluid likely lead
to an imbalance between antioxidants and ROS, resulting in
OS.
Several biochemical factors contribute to SHV.
Mendeluk et al. reported that semen samples with high
structural viscosity were often less consistent throughout
the sample due to highly organized protein networks (34),
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possibly due to the presence of structurally complex
molecules (35). The liquefaction of semen is activated by
ethylenediaminetetraacetic acid (EDTA) (36). What is
more is that Menduluk et al. was able to show that the
presence of EDTA did not have a significant effect on SHV
(34). This supports the theory by Amelar which suggests
that normal semen coagulation and SHV are controlled by
different factors (37). Furthermore other biochemical
factors have been associated with SHV, including zinc,
calcium, and prostate-specific antigen concentrations (6,
34). The liquefaction of coagulated semen is inhibited by
the presence of zinc; lower zinc concentrations have been
found in hyperviscous semen samples when compared to
samples with normal viscosity (38).
Semen coagulation and liquefaction depends on
the proteins in the secretions of the male accessory sex
glands, including the seminal vesicles and prostate (39, 40,
41). Dysfunction of either of these glands results in
hyperviscosity. A study by Gonzales et al. showed that
SHV is associated with low sperm concentration, low
sperm motility, low sperm vitality, and hypofunction of the
seminal vesicles (2). They also reported that with
hypofunction of the prostate or dysfunction of both the
prostate and seminal vesicles, no significant correlation
exists between hypofunction and SHV. This suggests that
proper functioning of the seminal vesicles is required for
normal viscosity. When there is less secretion from the
seminal vesicles, the prostatic fluid secretion increases; the
excess prostatic fluid may account for increased semen
viscosity (2). However, in another study it was found that
significantly lower levels of prostate-specific antigen (PSA)
in hyperviscous semen when compared to normal controls
(6). PSA is a proteolytic enzyme secreted by the prostate
that is involved in the liquefaction process. Zinc is secreted
by the prostate, and both the decreased levels of PSA and
zinc in semen with SHV suggest that hypofunction of the
prostate contributes to the development of SHV.
Genetic factors can furthermore play a role in the
development of SHV. SHV is considered a clinical
consequence of cystic fibrosis; Rossi et al. found an
association between hyperviscous consistency of semen
and gene mutations and variant tracts of the cystic fibrosis
transmembrane conductance regulator (CFTR) (42). Rossi
et al. subsequently theorized that cystic fibrosis can
possibly be a genetic contributor to SHV.
6. SPERM AND SEMEN PARAMETERS IN SHV
SHV, and the factors that contribute to SHV,
negatively affect sperm and semen parameters.
Hyperviscous semen physically affects the movement of
sperm. SHV has been shown to affect kinetics parameters
such as motility, velocity, and the linear direction of sperm
(43). SHV produces a trapping effect, inhibiting normal
sperm movement through the female reproductive tract (2).
SHV gives rise to asthenozoospermia through
biochemical factors. Past studies have shown that zinc
concentrations have a positive correlation with sperm
motility (44, 45). However, Mankad et al. found no
significant correlation (38), and it has been shown that high
seminal zinc concentrations negatively affect progressive
sperm motility (46). Decreased total antioxidant capacity
has also been associated with asthenozoospermia (47) and
may play a role in SHV. OS and high seminal ROS levels
in SHV are related to SHV decreased sperm parameters
such as motility and increased sperm DNA damage (7).
Studies have shown that the viscosity of seminal fluid
affects the energy required by sperm to reach translational
velocity (19). In the study by Gonzales et al., sperm
concentration, motility, vitality, and fructose concentrations
were decreased in samples with high viscosity (2). Elzanaty
et al. reported that seminal fructose levels were the only
parameter to significantly predict hyperviscosity in semen
samples (6). As increased ATP content per sperm has been
found in semen samples with higher viscosity when
compared to samples with normal viscosity (43, 48), it can
point to the fact that normal sperm movement is impaired
and ATP is not being consumed in hyperviscous semen.
SHV has been associated with poor semen
quality, changes in chromatin stability, and decreased
sperm count (2, 49). Gopalkrishnan et al. found that in
semen samples with abnormal viscosity, sperm chromatin
integrity was significantly lower when compared to
controls with normal semen viscosity (49). The results from
another study showed that semen with hyperviscosity
exhibited high sperm chromatin stability, which is
attributed to the presence of zinc-chelating agents (50).
These characteristics in SHV may be due to the fact that
sperm chromatin stability depends on secretions of the
prostate and seminal vesicles (51), including zinc chelators
that reduce the zinc content in sperm chromatin (52). A
significant decrease in sperm count in men with SHV has
been found (49), while Mankad et al. reported a statistically
significant positive correlation between zinc concentrations
and sperm count (38).
7. SHV AND FERTILITY
SHV can lead to infertility in males through
impairment of normal sperm movement. SHV and the
factors that contribute to the condition can also lead to in
vivo complications as well as have consequences in vitro
and in an assisted reproductive technology (ART) setting.
As seminal plasma plays a role in events leading
to fertilization, hyperviscosity of the seminal plasma
contributes to a decrease in sperm function. Seminal
plasma has a significant effect on human sperm-zona
pellucida binding both in vivo and in vitro (53). In one
study, researchers determined that seminal plasma
improved the entry of sperm into the cervical mucus, and
played a role in maintaining sperm swimming speed after
mucus penetration (54).
Soluble proteins secreted into the seminal fluid
play a role in the maturation of sperm by affecting the
distribution of surface charges across the sperm membrane
(55). In addition, seminal plasma has a protective
mechanism in preventing peroxidative breakdown of
phospholipids by fatty acid peroxides, which could lead to
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membrane damage and loss of motility (56). Nuclear
decondensation of sperm and sperm chromatin instability
has also been associated with seminal plasma (51).
The hyperviscosity of semen may impair any of
these functions. Studies have shown that hyperviscous
semen samples have infrequent consistency, possibly due to
the presence of structurally complex molecules such as
glycoproteins (7). These glycoproteins are incorporated
into the sperm membrane and are involved in zona
pellucida recognition by sperm and the acrosome reaction
(57). Because of this, SHV contributes to lower fertilization
rates after in vitro fetilization (IVF) and impairment of
embryo development (7). Similarly, SHV has been
associated with poor outcome of controlled ovarian
hyperstimulation (COH) and intrauterine insemination
(IUI) (58), although SHV does not have a negative impact
on inctracytoplasmic sperm injection (ICSI) (7). OS present
in SHV causes potential infertility through sperm
membrane and DNA damage, which not only has
consequences in sperm function but also embryo
development and pregnancy rates (59). These factors
indicate that SHV can more than likely be used as an
indicator of poor outcome from certain ART procedures, as
well as disrupted embryo development and failed
pregnancy (7).
8. TREATMENT
Semen hyperviscosity can be treated
successfully in vitro by traditional methods as well as by
recently developed methods. Hyperviscous semen is
commonly diluted or drawn into a hypodermic needle
and forced through in order to overcome the elevated
viscosity, although these methods are unlikely to be
completely effective because SHV is not completely a
mechanical phenomenon (7). More direct treatments of
patients presenting with SHV include over hydration,
prostatic massage, and the use of parenteral
hyaluronidase. These methods showed limited success
and have proven not to be too effective (60).
Less dated methods used in sperm preparation
for ART procedures have been shown to improve semen
and sperm parameters of infertile males. Honea et al.
found that the use of limited proteolysis by using α-
chymotrypsin in the treatment of SHV was effective for
an in vitro setting such as IVF or IUI (61). Zavos et al.
more recently reported that limited proteolysis by α-
chymotrypsin was effective in improving the use and
handling of hyperviscous semen samples, and that
treatment with α-chymotrypsin assisted in the recovery
of high quality sperm in greater numbers than in
hyperviscous samples not treated with α-chymotrypsin
(62). Other mucolytic agents that have been used in the
treatment of SHV include α-amylase, dithiothreitol, and
pancreatic dornase (63, 64). Anti-inflammatory agents
can be used in vivo to treat patients with lesser degrees
of SHV, while treatment in patients with severe SHV
showed some improvement (15). Antibiotics can also be
implemented in vivo for the management of SHV in
cases of infection and leukocytospermia (21).
9. CONCLUSION
SHV is caused by multiple contributing factors,
such as infection, inflammation, leukocytospermia,
hypofunction of the male sex accessory glands, OS, and
genetic factors. SHV leads to subfertility through a trapping
effect, asthenozoospermia, decreased sperm count, and
through disruption of events leading to fertilization
including sperm-oocyte fusion, entry into the cervical
mucus, distribution of surface charges on the sperm
membrane, prevention of the peroxidation reaction, and the
maintenance of sperm chromatin stability. SHV often leads
to consequences in fertilization rate, pregnancy rate, and
embryo development. SHV can be treated by conventional
methods such as treatments with a hypodermic needle,
mucolytic enzymes, and antibiotics and anti-inflammatory
agents in certain cases. While the causes and consequences
of SHV have been studied in the past, further research is
still necessary in order to better understand the contributors
to the development of hyperviscous semen and the
mechanisms through which hyperviscosity impairs male
fertility both in vivo and in vitro.
10. PERSPECTIVE
SHV affects a significant number of the male
population and can lead to decreased fertility. While there
are several known causes and consequences of SHV, some
are simply hypothesized or not entirely confirmed through
scientific research. Methods do exist for measuring degrees
of viscosity, as well as for treatment of the conditions and
infections that lead to subfertility associated with SHV.
However, further research into possible treatments for and
causes of SHV is necessary in order to improve fertility and
the success of current ART procedures.
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